Drug Profile
Research programme: Parkinson's disease therapeutics - Selonterra
Latest Information Update: 10 Mar 2023
Price :
$50
*
At a glance
- Originator Selonterra
- Class Antiparkinsonians; Small molecules
- Mechanism of Action Alpha-synuclein modulators; LRRK2 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Parkinson's disease
Most Recent Events
- 10 Mar 2023 Early research is still ongoing in Parkinson's disease in USA (unspecified route)
- 28 Feb 2021 No recent reports of development identified for research development in Parkinson's-disease in USA
- 23 Jan 2017 Early research in Parkinson's disease in USA (PO)